Phenylbutyrate Sensitizes Human Glioblastoma Cells Lacking Wild-Type P53 Function to Ionizing Radiation

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 1, 2007, Pages 214-220

  Lopez, Carlos A ^a   Feng, Felix Y ^a   Herman, Joseph M ^b   Nyati, Mukesh K ^a   Lawrence, Theodore S ^a   Ljungman, Mats ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; HDAC; p53; Phenylbutyrate; Radiation

Indexed keywords

CELLS; GROWTH KINETICS; IONIZING RADIATION; MEDICAL PROBLEMS; TUMORS;

CEREBROSPINAL FLUID PENETRATION; GLIOBLASTOMA; HISTONE DEACETYLASE (HDAC) INHIBITORS; PHENYLBUTYRATE;

ENZYME INHIBITION;

ARYLBUTYRIC ACID DERIVATIVE; HISTONE H3; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RADIOSENSITIVITY; RADIOSENSITIZATION; WESTERN BLOTTING;

ACETYLATION; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; GLIOBLASTOMA; HISTONE DEACETYLASES; HISTONES; HUMANS; PHENYLBUTYRATES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547850180     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.069     Document Type: Article

References (36)

1. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5 (2006) 37-50
2. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1 (2001) 194-202
3. Dyer E.S., Paulsen M.T., Markwart S.M., et al. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int J Cancer 101 (2002) 496-499
4. Goh M., Chen F., Paulsen M.T., et al. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 3 (2001) 331-338
5. Maestri N.E., Hauser E.R., Bartholomew D., et al. Prospective treatment of urea cycle disorders. J Pediatr 119 (1991) 923-928
6. Resar L.M., Segal J.B., Fitzpatric L.K., et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 24 (2002) 737-741
7. Collins A.F., Pearson H.A., Giardina P., et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial. Blood 85 (1995) 43-49
8. Carducci M.A., Gilbert J., Bowling M.K., et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7 (2001) 3047-3055
9. Phuphanich S., Baker S.D., Grossman S.A., et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. Neuro-oncol 7 (2005) 177-182
10. Berg S., Serabe B., Aleksic A., et al. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol 47 (2001) 385-390
11. Baker M.J., Brem S., Daniels S., et al. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol 59 (2002) 239-242
12. Maslak P., Chanel S., Camacho L.H., et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20 (2006) 212-217
13. Camphausen K., Cerna D., Scott T., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114 (2005) 380-386
14. Camphausen K., Burgan W., Cerra M., et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64 (2004) 316-321
15. Chinnaiyan P., Vallabhaneni G., Armstrong E., et al. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62 (2005) 223-229
16. Kim J.H., Shin J.H., and Kim I.H. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 59 (2004) 1174-1180
17. Lawrence T.S., Davis M.A., Maybaum J., et al. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res 52 (1992) 3698-3704
18. Fertil B., Dertinger H., Courdi A., et al. Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiat Res 99 (1984) 73-84
19. Gilbert J., Baker S.D., Bowling M.K., et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7 (2001) 2292-2300
20. Munshi A., Kurland J.F., Nishikawa T., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11 (2005) 4912-4922
21. Chung Y.L., Lee M.Y., Wang A.J., et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8 (2003) 707-717
22. Lu Q., Yang Y.T., Chen C.S., et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem 47 (2004) 467-474
23. Li X.N., Parikh S., Shu Q., et al. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 10 (2004) 1150-1159
24. Leng Y., and Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26 (2006) 7502-7512
25. Chung D.H., Zhang F., Chen F., et al. Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis. Radiat Res 149 (1998) 187-194
26. Van Meir E.G., Kikuchi T., Tada M., et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54 (1994) 649-652
27. O'Connor P.M., Jackman J., Bae I., et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57 (1997) 4285-4300
28. Gomez-Manzano C., Fueyo J., Kyritsis A.P., et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56 (1996) 694-699
29. Thomas C., Ely G., James C.D., et al. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol (Berl) 101 (2001) 605-615
30. Ferrandina G., Filippini P., Ferlini C., et al. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol Res 12 (2000) 429-440
31. Biade S., Stobbe C.C., Boyd J.T., et al. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 77 (2001) 1033-1042
32. Zhang Y., Jung M., Dritschilo A., et al. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161 (2004) 667-674
33. Blagosklonny M.V., Trostel S., Kayastha G., et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 65 (2005) 7386-7392
34. Kim I.A., Shin J.H., Kim I.H., et al. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: Class differences and the potential influence of p53. Clin Cancer Res 12 (2006) 940-949
35. Flatmark K., Nome R.V., Folkvord S., et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 1 (2006) 25
36. Watanabe K., Tachibana O., Sata K., et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6 (1996) 217-224